Using CRISPR gene editing, a team from Children’s Hospital of Philadelphia (CHOP) and Penn Medicine have thwarted a lethal lung disease in an animal model in which a harmful mutation causes death within hours after birth.
This proof-of-concept study, published today in Science Translational Medicine, showed that in uteroediting could be a promising new approach for treating lung diseases before birth.
“The developing fetus has many innate properties that make it an attractive recipient for therapeutic gene editing,” said study co-leader William H. Peranteau, MD, an investigator at CHOP’s Center for Fetal Research, and a pediatric and fetal surgeon in CHOP’s Center for Fetal Diagnosis and Treatment. “Furthermore, the ability to cure or mitigate a disease via gene editing in mid- to late gestation before birth and the onset of irreversible pathology is very exciting. This is particularly true for diseases that affect the lungs, whose function becomes dramatically more important at the time of birth.”
The lung conditions the team is hoping to solve — congenital diseases such as surfactant protein deficiency, cystic fibrosis, and alpha-1 antitrypsin — are characterized by respiratory failure at birth or chronic lung disease with few options for therapies. About 22 percent of all pediatric hospital admissions are because of respiratory disorders, and congenital causes of respiratory diseases are often lethal, despite advances in care and a deeper understanding of their molecular causes. Because the lung is a barrier organ in direct contact with the outside environment, targeted delivery to correct defective genes is an attractive therapy.
“We wanted to know if this could work at all,” said study co-leader Edward E. Morrisey, PhD, a professor of Cardiovascular Medicine in the Perelman School of Medicine at the University of Pennsylvania. “The trick was how to direct the gene-editing machinery to target cells that line the airways of the lungs.”
The researchers showed that precisely timed in utero delivery of CRISPR gene-editing reagents to the amniotic fluid during fetal development resulted in targeted changes in the lungs of mice. They introduced the gene editors into developing mice four days before birth, which is analogous to the third trimester in humans.
The cells that showed the highest percentage of editing were alveolar epithelial cells and airway secretory cells lining lung airways. In 2018, a team led by Morrisey identified the alveolar epithelial progenitor (AEP) lineage, which is embedded in a larger population of cells called alveolar type 2 cells. These cells generate pulmonary surfactant, which reduces surface tension in the lungs and keeps them from collapsing with every breath. AEPs are a stable cell type in the lung and turn over very slowly, but replicate rapidly after injury to regenerate the lining of the alveoli and restore gas exchange.
In a second experiment, the researchers used prenatal gene editing to reduce the severity of an interstitial lung disease, surfactant protein C (SFTPC) deficiency, in a mouse model that has a common disease-causing mutation found in the human SFTPC gene. One hundred percent of untreated mice with this mutation die from respiratory failure within hours of birth. In contrast, prenatal gene editing to inactivate the mutant Sftpc gene resulted in improved lung morphology and survival of over 22 percent of the animals.
Future studies will be directed toward increasing the efficiency of the gene editing in the epithelial lining of lungs as well as evaluating different mechanisms to deliver gene editing technology to lungs. “Different gene editing techniques are also being explored that may one day be able to correct the exact mutations observed in genetic lung diseases in infants,” Morrisey said.
The Latest on: Gene editing
[google_news title=”” keyword=”gene editing” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Gene editing
- How the gene-editing technology CRISPR is changing tomatoes, grapes and cattleon March 1, 2024 at 12:27 pm
You've probably heard about the gene-editing technology CRISPR. The massive biotech breakthrough, which has emerged in the last decade, has mainly been touted for the ways it will let scientists edit ...
- Intellia Therapeutics, Inc.: Intellia Earnings: Early-Stage Gene Editing Pipeline Makes Progress; Shares Very Undervaluedon February 29, 2024 at 4:00 pm
Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats ...
- Gene Silencing Slashes Cholesterol in Mice—No Gene Edits Requiredon February 29, 2024 at 1:26 pm
With a single shot of an epigenetic editor, the mice’s cholesterol levels rapidly dropped, and stayed low for nearly a year without notable side effects.
- Novel Gene Editing Tool Improves Immune Cell Activityon February 29, 2024 at 8:00 am
Jennifer Doudna and Emmanuelle Charpentier were awarded the 2020 Nobel Prize in Chemistry for their pioneering work in gene editing. The gene editing techn | Immunology ...
- Why Cell And Gene Therapy Design Processes Need More Efficient Quality Controlson February 29, 2024 at 3:00 am
Drugmakers must make the entire drug testing and quality control process as efficient and innovative as the drug discovery method itself.
- The Fight to Pay for Gene Therapyon February 29, 2024 at 2:01 am
There is new hope for seemingly incurable diseases, but the treatments will be truly revolutionary only if they are available to everyone.
- ‘Bad’ cholesterol gene silenced without altering the DNA sequenceon February 28, 2024 at 11:30 pm
By silencing the gene responsible for regulating ‘bad’ cholesterol without altering the primary DNA sequence, researchers have shown that it’s possible to use epigenetic editing to treat diseases ...
- Ginkgo adds gene editing tools in buyout of Feng Zhang-founded startupon February 28, 2024 at 12:59 am
Ginkgo Bioworks has acquired a biotechnology startup co-founded by gene editing pioneer Feng Zhang, part of the cell engineering company’s plan to build up technologies that can help other companies ...
- Beam Rockets 26%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drugon February 27, 2024 at 1:04 pm
Beam stock launched to a year high Tuesday as enthusiasm grows for its next-generation form of gene editing. Please watch the video at Investors.com - CRSP Stock On Wild Ride After FDA's Historic ...
- Using CRISPR gene editing to prevent pigs from getting blue-ear pig diseaseon February 26, 2024 at 6:11 am
A team of bio-scientists affiliated with a host of institutions across the U.S. has developed a gene editing technique to produce newborn pigs immune to porcine reproductive and respiratory syndrome, ...
via Bing News